Emergent Biosolutions, Inc. (EBS): Price and Financial Metrics

Emergent Biosolutions, Inc. (EBS): $3.39

0.16 (+4.95%)

POWR Rating

Component Grades








Add EBS to Watchlist
Sign Up

Industry: Biotech




#81 of 360

in industry

EBS Price/Volume Stats

Current price $3.39 52-week high $13.67
Prev. close $3.23 52-week low $1.42
Day low $3.21 Volume 2,258,200
Day high $3.57 Avg. volume 3,620,707
50-day MA $2.13 Dividend yield N/A
200-day MA $4.28 Market Cap 175.89M

EBS Stock Price Chart Interactive Chart >


  • EBS scores best on the Growth dimension, with a Growth rank ahead of 97.05% of US stocks.
  • EBS's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
  • EBS ranks lowest in Sentiment; there it ranks in the 1st percentile.

EBS Stock Summary

  • With a one year PEG ratio of 0.03, EMERGENT BIOSOLUTIONS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 0.71% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, EMERGENT BIOSOLUTIONS INC is reporting a growth rate of -538.27%; that's higher than merely 2.38% of US stocks.
  • EMERGENT BIOSOLUTIONS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 150.84%, greater than the shareholder yield of 98.61% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to EMERGENT BIOSOLUTIONS INC, a group of peers worth examining would be ELAN, ADTH, BLIN, AMWL, and ADN.
  • EBS's SEC filings can be seen here. And to visit EMERGENT BIOSOLUTIONS INC's official web site, go to www.emergentbiosolutions.com.

EBS Valuation Summary

  • EBS's price/sales ratio is 0.1; this is 97.62% lower than that of the median Healthcare stock.
  • Over the past 208 months, EBS's EV/EBIT ratio has gone down 44.8.

Below are key valuation metrics over time for EBS.

Stock Date P/S P/B P/E EV/EBIT
EBS 2023-12-29 0.1 0.2 -0.2 -1.4
EBS 2023-12-28 0.1 0.2 -0.2 -1.4
EBS 2023-12-27 0.1 0.2 -0.2 -1.4
EBS 2023-12-26 0.1 0.2 -0.2 -1.4
EBS 2023-12-22 0.1 0.2 -0.2 -1.4
EBS 2023-12-21 0.1 0.2 -0.2 -1.4

EBS Growth Metrics

    Its 3 year cash and equivalents growth rate is now at 217.32%.
  • The 2 year cash and equivalents growth rate now stands at 139.96%.
  • Its 4 year revenue growth rate is now at 115.98%.
EBS's revenue has moved up $807,924,000 over the prior 49 months.

The table below shows EBS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1,513.4 202.1 53.5
2022-06-30 1,602.4 292.8 96.5
2022-03-31 1,757.2 278.7 157.5
2021-12-31 1,792.7 321.1 230.9
2021-09-30 1,652.5 237.2 227
2021-06-30 1,708.7 325.7 299.2

EBS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EBS has a Quality Grade of C, ranking ahead of 50.38% of graded US stocks.
  • EBS's asset turnover comes in at 0.604 -- ranking 57th of 681 Pharmaceutical Products stocks.
  • ARWR, IBIO, and MCRB are the stocks whose asset turnover ratios are most correlated with EBS.

The table below shows EBS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.604 0.623 0.227
2021-03-31 0.628 0.680 0.298
2020-12-31 0.607 0.663 0.247
2020-09-30 0.550 0.633 0.146
2020-06-30 0.536 0.645 0.152
2020-03-31 0.478 0.622 0.076

EBS Price Target

For more insight on analysts targets of EBS, see our EBS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $85.71 Average Broker Recommendation 1.69 (Moderate Buy)

Emergent Biosolutions, Inc. (EBS) Company Bio

Emergent BioSolutions is a biopharmaceutical company which develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company was founded in 1998 and is based in Gaithersburg, Maryland.

EBS Latest News Stream

Event/Time News Detail
Loading, please wait...

EBS Latest Social Stream

Loading social stream, please wait...

View Full EBS Social Stream

Latest EBS News From Around the Web

Below are the latest news stories about EMERGENT BIOSOLUTIONS INC that investors may wish to consider to help them evaluate EBS as an investment opportunity.

Why Is Icosavax (ICVX) Stock Up 46% Today?

Icosavax stock is up on Tuesday as investors react to an acquisition deal with AstraZeneca that values ICVX between $15 and $20 per share.

William White on InvestorPlace | December 12, 2023

EBS Stock Earnings: Emergent BioSolutions Misses EPS, Beats Revenue for Q3 2023

EBS stock results show that Emergent BioSolutions missed analyst estimates for earnings per share but beat on revenue for the third quarter of 2023.

InvestorPlace Earnings on InvestorPlace | December 12, 2023

Emergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue Estimates

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -1,100% and 5.94%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | December 11, 2023

Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine

The BARDA is exercising an option to procure additional doses of Emergent BioSolutions' (EBS) recently approved anthrax vaccine. Deliveries will likely be completed by the end of first-quarter 2024.

Yahoo | November 29, 2023

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)

GAITHERSBURG, Md., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services has awarded a $75 million option to Emergent’s existing contract (HHSO100201600030C) for the acquisition of newly licensed anthrax vaccine CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted). Deli

Yahoo | November 28, 2023

Read More 'EBS' Stories Here

EBS Price Returns

1-mo 105.45%
3-mo 41.84%
6-mo N/A
1-year -70.93%
3-year -96.42%
5-year -94.12%
YTD 41.25%
2023 -79.68%
2022 -72.83%
2021 -51.48%
2020 66.08%
2019 -8.99%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!